RxDoctor Payments DataLook up a doctor →

Jonathan Musmand, MD

Allergy & Immunology · Portland, MENPI 1982652707

Payments from drug & device makers

$239,240in general payments, 2019–2025

Across 854 payments — averaging $280.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$93K
  • Regeneron Healthcare Solutions, Inc.$83K
  • Sanofi$51K
  • CSL Behring$7K
  • GSK$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • plus $4K from 25 others

What the payments were for

  • Consulting fees$5,4522%
  • Speaking & faculty fees$195,10382%
  • Travel & lodging$18,2998%
  • Food & beverage$20,2368%
  • Education$1510%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy & immunology providers in Maineto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$143,741
Medicare patients
249
Services billed
6,260

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter259$237,376
TezspireTezepelumab-Ekko41$182,449
Dupixent PenDupilumab46$177,620
Breo ElliptaFluticasone/Vilanterol175$131,306
Dupixent SyringeDupilumab22$82,191
Fasenra PenBenralizumab12$71,140
DuleraMometasone/Formoterol86$38,863
Breztri AerosphereBudesonide/Glycopyr/Formoterol38$34,630
Advair HfaFluticasone Propion/Salmeterol49$24,439
SymbicortBudesonide/Formoterol Fumarate45$15,848
Arnuity ElliptaFluticasone Furoate39$14,117
Spiriva RespimatTiotropium Bromide18$10,978
Epinephrine36$8,966
Incruse ElliptaUmeclidinium Bromide14$6,340
Pulmicort FlexhalerBudesonide12$4,177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta$1,526$389,139487 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort, Pulmicort Flexhaler$92,995$237,104136 claims
MerckDulera$85$38,86386 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy & immunology providers in Maineon file to place this against a meaningful peer group, so we don't.

Other allergy & immunology in Portland

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →